73 results
8-K
EX-1.1
ESPR
Esperion Therapeutics Inc.
22 Jan 24
Esperion Announces Proposed Public Offering of Common Stock
6:10am
other party, (c) no Underwriter has assumed or will assume an advisory or fiduciary responsibility in favor of the Company with respect
424B5
ESPR
Esperion Therapeutics Inc.
22 Jan 24
Prospectus supplement for primary offering
6:04am
no responsibility for, and can provide no assurance as to the reliability of, such information. We are not making an offer to sell the securities … in this prospectus supplement has been prepared by, and is the responsibility of, our management. Ernst & Young LLP has not audited, reviewed, compiled
8-K
ESPR
Esperion Therapeutics Inc.
18 Jan 24
Regulation FD Disclosure
4:03pm
by, and is the responsibility of, the Company’s management. Ernst & Young LLP has not audited, reviewed, compiled, or performed any procedures
424B5
m9ci 38f9dmrqywn3
18 Jan 24
Prospectus supplement for primary offering
4:01pm
8-K
yu6683r6p
3 Jan 24
Esperion and Daiichi Sankyo Europe Announce $125 Million Amendment to Their Collaboration, Including Resolution of Pending Litigation
8:00am
8-K
EX-99.1
chfsgpr
4 May 23
Other Events
9:26am
8-K
EX-99.1
k6g 866bal4veip98npt
28 Apr 22
Esperion Announces the Appointment of Stephen Rocamboli to its Board of Directors
4:19pm
8-K
c940xawvn56s4l5cyx67
28 Apr 22
Esperion Announces the Appointment of Stephen Rocamboli to its Board of Directors
4:19pm
PRE 14A
wn16fgg txv4l
4 Apr 22
Preliminary proxy
4:03pm
8-K
cyddvmheufv0twt6o7e
1 Mar 22
Departure of Directors or Certain Officers
5:04pm
8-K
EX-99.1
l0f8s78w375ses5msg
4 Jan 22
Esperion Appoints Benjamin O. Looker as General Counsel
8:28am
8-K
ctaa6v 264x
4 Jan 22
Esperion Appoints Benjamin O. Looker as General Counsel
8:28am
8-K
EX-1.1
jlhl8
7 Dec 21
Esperion Announces Proposed Public Offering
4:01pm